News and Announcements
Positive Data on RECCE® 327 Against Neisseria gonorrhoeae in STD Animal Model
- Published May 03, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights:
- Statistically significant reduction of Neisseria gonorrhoeae bacteria in reproductive organs of female mice
- RECCE® 327 outperformed market approved drug Meropenem in most instances
Sydney Australia, 4 May 2020: Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing a New Class of Broad-Spectrum Synthetic antibiotics, today announced positive efficacy showing significant antibacterial activity against Neisseria gonorrhoeae bacteria in mice treated with its lead compound RECCE® 327.
The study was conducted by an independent Contract Research Organisation to assess the dose-dependency of RECCE® 327 and in-vivo antibacterial activity against Neisseria gonorrhoeae (N. gonorrhoeae), a species of Gram-negative bacteria, and the second most common sexually transmitted infection (STI) globally.1 The recognised vaginal infection model met its primary endpoint of a reduction in bacterial load compared to vehicle infected control evaluated on the seventh day following dosing.
To read the full update click here.
About Recce Pharmaceuticals Ltd (ASX: RCE)
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad-spectrum activity designed to address the urgent global health problem of antibiotic-resistant superbugs.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
